| International Session（Symposium）9(JGES・JSGE・JSGS・JSGCS) |
| Sat. November 7th 9:00 - 11:30 Room 11: Portopia Hotel South Wing Topaz |
| Current status and future perspectives in the management of early gastric cancer in Japan | |||
| Junichi Akiyama1, Chizu Yokoi1, Naomi Uemura1 | |||
| 1National Center for Global Health and Medicine | |||
|
|||
|
|||
| Gastric cancer (GC) is the fifth most common cancer worldwide with 952,000 new patients diagnosed in 2012, and the third leading cause of cancer deaths. Incidence of GC is particularly high in Asian countries, which is attributed to the prevalence of Helicobacter pylori (Hp) infection. In Japan, the national health insurance system has covered eradication therapy for Hp infected chronic gastritis patients since 2013. Similarly, in 2014 the International Agency for Research on Cancer Working Group Report recommended that all countries explore the possibility of introducing population-based Hp screening and treatment programs as a strategy of GC preventions. To date, a number of clinical studies have been conducted to evaluate whether Hp eradication therapy reduces the risk of GC. Although several meta-analyses have been performed based on these studies, the conclusions were inconsistent and whether there exists 'a point of no return' still remains a matter of debate. In contrast, there has been an increase in the number of reported cases of early GC arising in the stomach without Hp infection (referred to as Hp-negative (or naive) GC (HpNGC)), even though its prevalence is estimated to be low. We will review the currently available data regarding post-eradication GC and HpNGC, and discuss future directions of the management of early gastric cancer in Japan. |
|||
|
Index Term 1: gastric cancer Index Term 2: Helicobacter pylori |
|||
| Page Top | |||